Jefferies Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Kelly Shi has maintained a Buy rating on Centessa Pharmaceuticals and increased the price target from $13 to $19.
September 11, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has reaffirmed its Buy rating on Centessa Pharmaceuticals and raised the price target from $13 to $19, indicating a positive outlook.
The increase in the price target from $13 to $19 by Jefferies suggests a strong positive outlook for Centessa Pharmaceuticals. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100